Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARO-RAGE in Mild Atopic Asthma
NCT07241546Phase 2Recruiting
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of ARO-RAGE in asthma, sponsored by Arrowhead Pharmaceuticals. Started Mar 2026; status: recruiting.
02
Drugs
ARO-RAGE
03
Conditions
asthma
Beyond the preview
Go deeper on NCT07241546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07241546.